The first procedure in the world designed to treat a patient using a bioengineered external liver was recently performed by a team at Intermountain Medical Center.

Detailed price information for Windtree Therapeutics Inc (WINT-Q) from The Globe and Mail including charting and trades.

United Therapeutics Corporation beats earnings expectations. Reported EPS is $6.63, expectations were $6.29. Operator: Good morning and welcome to the United Therapeutics Corporation First Quarter ...

United Therapeutics Corporation (NASDAQ:UTHR) Q4 2024 Earnings Call Transcript February 26, 2025 United Therapeutics Corporation beats earnings expectations. Reported EPS is $6.19, expectations ...

Dec. 16—United Therapeutics Corp., a Maryland-based biotechnology company with an artificial organ manufacturing research facility in Manchester's Millyard, says it's no longer pursuing plans ...

United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced the world’s first transplant of a UKidney, which it produced, into a living person on November 25 ...

A 19th-century timber building, which previously served as a tannery, now is home to an R&D facility that is developing 3D printed lungs for transplant. United Therapeutics had occupied 1.5 floors ...

Sep. 26—United Therapeutics Corp., a Maryland-based biotechnology company with an artificial organ manufacturing research facility in Manchester's Millyard, has signed a letter of intent to ...